JAZZ
Jazz Pharmaceuticals
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: JAZZ
- PE Ratio
As at Jun 12, 2026, the JAZZ stock has a price-to-earnings ratio of 490.55. This is based on the current EPS of $0.47 and the stock price of $230.56 per share.
JAZZ PE ratio history
The mean historical PE ratio of Jazz Pharmaceuticals over the last ten years is 42.25. The current 490.55 P/E ratio is 1,061% higher than the historical average. In the past ten years, JAZZ's PE ratio peaked in the Mar 2026 quarter at 402.23, with a price of $189.05 and an EPS of $0.47. The Sep 2019 quarter marked the lowest point at 12.11, with a price of $128.14 and an EPS of $10.58.
Jazz Pharmaceuticals PE ratio by year
Maximum annual increase: 389.8% in 2014
Maximum annual decrease: -84.36% in 2015
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | N/A | N/A | $170 | -$5.84 |
| 2024 | 13.59 | -27.64% | $123.15 | $9.06 |
| 2023 | 18.78 | N/A | $123 | $6.55 |
| 2022 | N/A | N/A | $159.31 | -$3.58 |
| 2021 | N/A | N/A | $127.4 | -$5.52 |
| 2020 | 38.56 | 138.17% | $165.05 | $4.28 |
| 2019 | 16.19 | -2.7% | $149.28 | $9.22 |
| 2018 | 16.64 | 0.48% | $123.96 | $7.45 |
| 2017 | 16.56 | -0.36% | $134.65 | $8.13 |
| 2016 | 16.62 | -36.39% | $109.03 | $6.56 |
| 2015 | 26.13 | -84.36% | $140.56 | $5.38 |
| 2014 | 167.07 | 389.8% | $163.73 | $0.98 |
| 2013 | 34.11 | 226.1% | $126.56 | $3.71 |
| 2012 | 10.46 | -18.47% | $53.25 | $5.09 |
| 2011 | 12.83 | -41.34% | $38.63 | $3.01 |
Jazz Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 402.23 | N/A | $189.05 | $0.47 |
| Dec 2025 | N/A | N/A | $170 | -$5.84 |
| Sep 2025 | N/A | N/A | $131.8 | -$5.99 |
| Jun 2025 | N/A | N/A | $106.12 | -$6.63 |
| Mar 2025 | 15.94 | 17.29% | $124.15 | $7.79 |
| Dec 2024 | 13.59 | -9.1% | $123.15 | $9.06 |
| Sep 2024 | 14.95 | -12.06% | $111.41 | $7.45 |
| Jun 2024 | 17 | -26.15% | $106.73 | $6.28 |
| Mar 2024 | 23.02 | 22.58% | $120.42 | $5.23 |
| Dec 2023 | 18.78 | -82.59% | $123 | $6.55 |
| Sep 2023 | 107.87 | N/A | $129.44 | $1.2 |
| Jun 2023 | N/A | N/A | $123.97 | -$1.44 |
| Mar 2023 | N/A | N/A | $146.33 | -$2.51 |
| Dec 2022 | N/A | N/A | $159.31 | -$3.58 |
| Sep 2022 | N/A | N/A | $133.29 | -$0.26 |
JAZZ Price vs fair value
JAZZ average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
The current PE ratio of JAZZ is higher than its 3, 5 and 10-year historical averages.
PE comparison
Jazz Pharmaceuticals's P/E of 490.55 is above the Healthcare sector and the industry average.
JAZZ PE vs peers
In comparison to its peer stocks NVS and TEVA, JAZZ's PE ratio is higher.
| Stock name | PE ratio | Market cap |
|---|---|---|
| NVS Novartis AG | 21.59 | $289.19B |
| TEVA Teva Pharmaceutical Industries Ltd | 24.59 | $39.23B |
| JAZZ Jazz Pharmaceuticals plc | 490.62 | $14.47B |
| PRGO PERRIGO Co plc | N/A | $1.48B |
Frequently asked questions
What is Jazz Pharmaceuticals's PE ratio?
The price to earnings ratio for JAZZ stock as of Jun 12, 2026, stands at 490.55.
What is the 3-year average PE ratio for Jazz Pharmaceuticals (JAZZ)?
The 3-year average price to earnings ratio for JAZZ stock is 76.67.
What is the 5-year average PE ratio for Jazz Pharmaceuticals (JAZZ)?
The 5-year average price to earnings ratio for JAZZ stock is 85.94.
What is the highest PE ratio for JAZZ?
The current PE of 490.55 represents the highest historical value in the last ten years.
How does the current PE ratio for JAZZ compare to its historical average?
JAZZ's current price to earnings ratio is 1,061% above its 10-year historical average.
Why is Jazz Pharmaceuticals's PE ratio so high?
JAZZ's stock price is trading at a higher multiple of earnings, which is why its PE ratio of 490.55 is considered high.
How is JAZZ's PE ratio calculated (Jazz Pharmaceuticals PE ratio formula)?
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jun 12, 2026), Jazz Pharmaceuticals's stock price is $230.56. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.47. Therefore, Jazz Pharmaceuticals's PE ratio for today is 490.55. PE RATIO(490.55) = STOCK PRICE($230.56) / TTM EPS($0.47)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.